Sanofi Archives - Page 6 of 7 - Medical Design Sourcing

Pharma 50: Here’s how the world’s largest pharma companies are doing

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies last year overcame clinical trial disruption and staffing hurdles to drive unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

Get the full story on our sister site Drug Discovery & Development.

Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system

[Image from Bigfoot Biomedical]Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system.

Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

The top 5 pharma firms by reputation

Photo by Anton on Unsplash

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.

Now ranked eighth overall, the pharma industry came in just ahead of the consumer services industry and just behind the automobiles and components sector.

Get the full story from our sister site, Pharmaceutical Processing World.

The top 5 pharma firms by reputation

Photo by Anton on Unsplash

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.

Now ranked eighth overall, the pharma industry came in just ahead of the consumer services industry and just behind the automobiles and components sector.

The pharma industry began to see its reputation improve beginning in the second quarter of 2020, when the industry claimed a leading role in pandemic recovery, according to RepTrak.

In the Asia-Pacific region, the pharmaceutical sector has the highest reputation of any industry, according to RepTrak’s report.

In creating the listing, RepTrack surveyed 68,577 people in 15 countries, asking them to a…

Sanofi to spend nearly $700M on new flu vaccine plant in Canada

[Photo from Unsplash]

Sanofi announced today that it will spend €600 million ($685 million) on a new plant in Toronto to produce its differentiated influenza vaccines.

The Paris-based pharma giant’s Fluzone high-dose quadrivalent influenza vaccine has four times more antigen than a standard-dose vaccine. The vaccine’s creators specifically designed it to provide superior protection against influenza for older adults.

The new plant will provide additional antigen and filling capacity for Fluzone, boosting supplies in Canada, the U.S. and Europe. The goal is to enhance preparedness for future influenza pandemics. While the present COVID-19 pandemic involves a novel coronavirus, influenza viruses have historically been a serious problem — most notably in 1918, which saw worldwide flu deaths in the millions.

Sanofi officials consider vaccines a key growth driver for the company in the fu…

GSK, Sanofi launch new COVID-19 vaccine study for protein-based vaccine

Sanofi (NYSE:SNY) and Glaxo Smith Kline (NYSE:GSK) are moving forward with their development plans of a COVID-19 vaccine.

In December, the two companies announced that their vaccine development efforts had been delayed after the product failed to mount a robust immune response in older adults.

The two companies believe the setback resulted from an insufficient amount of the antigen in the vaccine. They have since revised the formulation and have launched a Phase 2 study to test the adjuvanted recombinant protein-based COVID-19 vaccine candidate.

If the study meets its primary endpoints, the companies will launch a Phase 3 trial in the second quarter of the year with authorization potentially following in the fourth quarter of the year.

“We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data,’ said Thomas Triomphe, executive vice president and head of Sanofi Pasteur, in a statement…

Biden announces $4B to support global vaccinations worldwide

[Photo by Daniel Schludi on Unsplash]President Joe Biden announced that the U.S. is set to provide $4 billion to the COVAX Facility to support access to safe and effective COVID-19 vaccines.

Money appropriated by a December 2020 Congressional vote will comprise an initial $2 billion contribution to Gavi, the Vaccine Alliance for the COVAX advance market commitment (AMC) covering 92 low- and middle-income economies, according to a White House Statement.

Get the full story at our sister site, Pharmaceutical Processing World.

Biden announces $4B to support global vaccinations worldwide

President Joe Biden announced that the U.S. is set to provide $4 billion to the COVAX Facility to support access to safe and effective COVID-19 vaccines.

Money appropriated by a December 2020 Congressional vote will comprise an initial $2 billion contribution to Gavi, the Vaccine Alliance for the COVAX advance market commitment (AMC) covering 92 low- and middle-income economies, according to a White House Statement.

Additionally, the U.S. will release a further $2 billion through 2021 and 2022, with the first $500 million set to be made available when existing donor pledges are fulfilled and initial doses are delivered to AMC countries.

Biden also called on the G7 and other partners to work alongside Gavi to continue to build support for global COVID-19 vaccination, targeting urgent vaccine manufacturing, supply and delivery needs.

“The United States’ contribution is designated to help Gavi prevent, prepare for, and respond to coronavirus th…

Which companies will likely produce the most COVID-19 vaccine in 2021?

Photo by Markus Spiske on Unsplash

Since the beginning of the pandemic, much of society has pinned its hopes on the availability of a vaccine. Now that several are available across the world, there is hope, said Dr. Anthony Fauci, chief medical advisor to President Joe Biden, in a recent JAMA interview. “There’s light at the end of the tunnel.”

One thing that will make the light at the end of the tunnel brighter as we head into the spring is the greater availability of vaccine doses. “The discordance between supply and demand will be diminished,” Fauci said.

The roster of companies producing vaccines is steadily increasing, making it possible to vaccinate a substantial portion of the world’s population this year. (Note: Most of the companies in this list have two-dose vaccines.)

Here’s a roundup of notable companies’ production targets for 2021:

AstraZeneca and Oxford University: Up to 3…

Sanofi rises on mixed bag Q4, expected 2021 EPS growth

Sanofi (NYSE:SNY) shares ticked up this morning on fourth-quarter results that were mixed compared to the consensus forecast.

The (LOCATION)-based company posted profits of $1.3 billion, or $1.03 per share, on sales of $11.3 billion, marking a -2.4% year-over-year revenue decline for the three months ended Dec. 31, 2020.

Adjusted to exclude one-time items, earnings per share were $1.46, 77¢ ahead of Wall Street, where analysts were looking for sales of $11.4 billion.

“While last year was an extraordinarily challenging year for all, I am incredibly proud of the measurable progress we made within the backdrop of a global pandemic,” Sanofi CEO Paul Hudson said in a news release. “Our teams across the world have relentlessly delivered on our strategy with a sharpened focus on operating and financial efficiencies. We bolstered our R&D pipeline with the completion of the Synthorx and Principia acquisitions, met several regulatory milestones to …

Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer

Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine.

Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020.

The deal between Sanofi provides BioNTech access to its infrastructure and expertise to produce over 125 million doses of the COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi’s production facilities in Frankfurt starting in the summer of 2021, according to a news release.

Get the full story at our sister site, Pharmaceutical Processing World.

Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer

Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine.

Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020.

The deal between Sanofi provides BioNTech access to its infrastructure and expertise to produce over 125 million doses of the COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi’s production facilities in Frankfurt starting in the summer of 2021, according to a news release.

“We are very conscious that the earlier vaccine doses are available, the more lives can potentially be saved. Today’s announcement is a pivotal step towards our industry’s collective goal of putting all the effort in to curb this pandemic,” Sanofi CEO Paul Hudson said in the release. “Although vaccination campaigns have started a…